For example, PD-L1 overexpression in hepatocellular cancer, pancreatic cancer, renal cell carcinoma, ovarian cancer, and bladder cancer correlates with poor clinical outcomes; however, the prognostic value of PD-L1 is not absolute and depends on a variety of factors. This evidence concerns the gene CD274 and renal cell carcinoma.